Your browser doesn't support javascript.
loading
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution.
Xiao, Yufeng; Yuan, Yaxia; Liu, Yi; Lin, Zongtao; Zheng, Guangrong; Zhou, Daohong; Lv, Dongwen.
  • Xiao Y; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1333 Center Drive, Gainesville, Florida 32610, United States.
  • Yuan Y; Department of Biochemistry and Structural Biology and Center for Innovative Drug Discovery, School of Medicine, University of Texas Health San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States.
  • Liu Y; Mays Cancer Center, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States.
  • Lin Z; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1333 Center Drive, Gainesville, Florida 32610, United States.
  • Zheng G; Department of Biochemistry and Molecular Biophysics, Washington University in St. Louis, St. Louis, Missouri 63110, United States.
  • Zhou D; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1333 Center Drive, Gainesville, Florida 32610, United States.
  • Lv D; Department of Biochemistry and Structural Biology and Center for Innovative Drug Discovery, School of Medicine, University of Texas Health San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States.
J Med Chem ; 67(14): 11580-11596, 2024 Jul 25.
Article en En | MEDLINE | ID: mdl-38981094
ABSTRACT
Targeted protein degradation (TPD), including the use of proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) to degrade proteins, is an emerging strategy to develop novel therapies for cancer and beyond. PROTACs or MGDs function by inducing the proximity between an E3 ligase and a protein of interest (POI), leading to ubiquitination and consequent proteasomal degradation of the POI. Notably, one major issue in TPD is the lack of ligandable E3 ligases, as current studies predominantly use CUL4CRBN and CUL2VHL. The TPD community is seeking to expand the landscape of ligandable E3 ligases, but most discoveries rely on phenotypic screens or serendipity, necessitating systematic target deconvolution. Here, we examine and discuss both current and emerging E3 ligase deconvolution approaches for degraders discovered from phenotypic screens or monovalent glue chemistry campaigns, highlighting future prospects for identifying more ligandable E3 ligases.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ubiquitina-Proteína Ligasas / Proteolisis Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ubiquitina-Proteína Ligasas / Proteolisis Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article